Scientists in Britain have identified a genetic mutation involved in certain types of lung cancer and said the breast cancer drug Herceptin might work in patients who have it. The gene called ERBB2 is linked to four percent of non-small-cell lung cancers (NSCLC), which account for about 75 percent of all cases of the deadly disease.
